Nasal spray shows promise for depression that Won't quit

NCT ID NCT05660642

Recruiting now Symptom relief Sponsor: Beckley Psytech Limited Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study tests a new nasal spray called BPL-003, combined with psychological support, in 64 people with treatment-resistant depression (depression that hasn't improved with at least two prior medications). The goal is to see if it's safe and how it affects mood. Participants will receive one or two doses and be monitored for side effects and changes in depression symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BPL-003 (intranasal)
What this could lead to: If successful, this could point toward a new treatment option for people with depression that hasn't responded to standard medications.
What could go wrong: This is an early Phase 2a study with only 64 participants, open-label (no placebo), so results may not be definitive. Risks include side effects and potential for suicidal thoughts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TREATMENT RESISTANT DEPRESSION

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Hammersmith Medicines Research
RECRUITING

London, United Kingdom
King's College London, Clinical Trials Facility
COMPLETED

London, United Kingdom
MAC Clinical Research
RECRUITING

Liverpool, L34 1BH, United Kingdom

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.